Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression.

doi:10.1056/NEJMoa1904398

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression.

The New England journal of medicine - 19 Mar 2020

Swindells Susan, Andrade-Villanueva Jaime-Federico, Richmond Gary J, Rizzardini Giuliano, Baumgarten Axel, Masiá Mar, Latiff Gulam, Pokrovsky Vadim, Bredeek Fritz, Smith Graham, Cahn Pedro, Kim Yeon-Sook, Ford Susan L, Talarico Christine L, Patel Parul, Chounta Vasiliki, Crauwels Herta, Parys Wim, Vanveggel Simon, Mrus Joseph, Huang Jenny, Harrington Conn M, Hudson Krischan J, Margolis David A, Smith Kimberly Y, Williams Peter E, Spreen William R

Abstract excerpt

BACKGROUND: Simplified regimens for the treatment of human immunodeficiency virus type 1 (HIV-1) infection may increase patient satisfaction and facilitate adherence. METHODS: In this phase 3, open-label, multicenter, noninferiority trial involving patients who had had plasma HIV-1 RNA levels of less than 50 copies per milliliter for at least 6 months while taking standard oral antiretroviral therapy, we randomly...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Anti-Retroviral Agents

Share to CD4 Lymphocyte Count

Share to Injections, Intramuscular

Share to Maintenance Chemotherapy

Share to Patient Reported Outcome Measures

Share to Pyridones

Share to Rilpivirine

Source

Open in PubMed

Identifiers

PMID: 32130809
DOI: 10.1056/NEJMoa1904398

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression.PMID 32130809Read ↗

Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.Semantic proximity Read ↗

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.Semantic proximity Read ↗

Efficacy of initial antiretroviral therapy for HIV-1 infection in adults: a systematic review and meta-analysis of 114 studies with up to 144 weeks' follow-up.Semantic proximity Read ↗

Genotyping not required for sustained effectiveness of long-acting cabotegravir plus rilpivirine: evidence from the RELATIVITY cohort.Semantic proximity Read ↗

Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500 000 copies/mL: week 48 outcomes from ACTG 5353.Semantic proximity Read ↗

Long-acting antiretroviral therapy effectiveness and patient satisfaction using patient questionnaires: data from a real-world settingSemantic proximity Read ↗

Virological Failure After Switch to Long-Acting Cabotegravir and Rilpivirine Injectable Therapy: An In-depth Analysis.Semantic proximity Read ↗

Class-sparing regimens for initial treatment of HIV-1 infection.Semantic proximity Read ↗

Raltegravir 1200 mg Once Daily as Maintenance Therapy in Virologically Suppressed HIV-1 Infected Adults : QDISS Open-Label TrialSemantic proximity Read ↗

Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.Semantic proximity Read ↗

Dolutegravir Monotherapy Versus Dolutegravir/Abacavir/Lamivudine for Virologically Suppressed People Living With Chronic Human Immunodeficiency Virus Infection: The Randomized Noninferiority MONotherapy of TiviCAY Trial.Semantic proximity Read ↗

Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.